KR100793204B1 - Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient - Google Patents
Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient Download PDFInfo
- Publication number
- KR100793204B1 KR100793204B1 KR1020060044651A KR20060044651A KR100793204B1 KR 100793204 B1 KR100793204 B1 KR 100793204B1 KR 1020060044651 A KR1020060044651 A KR 1020060044651A KR 20060044651 A KR20060044651 A KR 20060044651A KR 100793204 B1 KR100793204 B1 KR 100793204B1
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- composition
- herbal
- extract
- coronary heart
- Prior art date
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 title abstract description 19
- 239000004615 ingredient Substances 0.000 title description 11
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 235000008434 ginseng Nutrition 0.000 claims abstract description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 239000012676 herbal extract Substances 0.000 claims abstract description 17
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 16
- 229940010454 licorice Drugs 0.000 claims abstract description 16
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- 240000000249 Morus alba Species 0.000 claims abstract description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 13
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 12
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 12
- 241001061264 Astragalus Species 0.000 claims abstract description 11
- 210000004233 talus Anatomy 0.000 claims abstract description 11
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 10
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 239000000052 vinegar Substances 0.000 claims abstract description 4
- 235000021419 vinegar Nutrition 0.000 claims abstract description 4
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract 3
- 244000241838 Lycium barbarum Species 0.000 claims abstract 3
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- 241001632576 Hyacinthus Species 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 32
- 235000012000 cholesterol Nutrition 0.000 abstract description 13
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 abstract description 11
- 208000026758 coronary atherosclerosis Diseases 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 9
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 4
- 206010012655 Diabetic complications Diseases 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 25
- 241000411851 herbal medicine Species 0.000 description 20
- 240000004371 Panax ginseng Species 0.000 description 19
- 241000202807 Glycyrrhiza Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 244000241872 Lycium chinense Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000736199 Paeonia Species 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 230000037356 lipid metabolism Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 229940124595 oriental medicine Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000002789 Panax ginseng Nutrition 0.000 description 4
- 241000756042 Polygonatum Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 241000045403 Astragalus propinquus Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- 244000167222 Acanthopanax sessiliflorus Species 0.000 description 2
- 235000017615 Acanthopanax sessiliflorus Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000218213 Morus <angiosperm> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001625885 Polygonatum odoratum var. pluriflorum Species 0.000 description 2
- 241001347459 Prunella vulgaris var. lilacina Species 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- BKNDOJUZMXDRDL-UHFFFAOYSA-N 4-butylcyclohexa-1,5-diene-1,4-diol Chemical compound CCCCC1(O)CC=C(O)C=C1 BKNDOJUZMXDRDL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000037488 Coccoloba pubescens Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000293610 Morus bombycis Species 0.000 description 1
- 241000301120 Morus lhou Species 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000695852 Polygonatum robustum Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000046342 Prorocentrum koreanum Species 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 230000004530 effect on cardiovascular disease Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000010413 gardening Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- ZPCAZHPYLUKSMY-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZPCAZHPYLUKSMY-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229910000898 sterling silver Inorganic materials 0.000 description 1
- 239000010934 sterling silver Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- -1 yellow Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 혈장 총 콜레스테롤 및 중성지방의 농도를 감소시키는 효과를 갖는 한약재 추출물을 유효성분으로 함유하는 조성물에 관한 것으로, 보다 구체적으로는 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a composition containing a herb extract having an effect of reducing the concentration of total cholesterol and triglycerides as an active ingredient, more specifically white ginseng, Astragalus, licorice, wolfberry, mulberry leaves, brown roots, vinegar The present invention relates to a pharmaceutical composition for the prevention or treatment of coronary heart disease or atherosclerosis, which comprises a Chinese herbal extract consisting of, ogalpi, schisandra chinensis, golden, powdered, yellow, peony and raw.
본 발명에 따르면, 상기 한약재 조성물은 혈장 총 콜레스테롤 및 중성지방의 농도를 감소시킴으로써 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 의약품으로 사용될 수 있다.According to the present invention, the herbal composition can be used as a medicament for preventing or treating coronary heart disease or atherosclerosis by reducing the concentration of total cholesterol and triglycerides in plasma.
당뇨합병증, 콜레스테롤, 한약재 추출물. Diabetic complications, cholesterol, herbal extracts.
Description
도 1은 대조군과 한약재 조성물 섭취군에서 당뇨동물 모델의 혈장 콜레스테롤 농도를 나타낸 것이다.Figure 1 shows the plasma cholesterol concentration of the diabetic animal model in the control group and the herbal medicine intake group.
도 2는 대조군과 한약재 조성물 섭취군에서 당뇨동물 모델의 혈장 중성지방 농도를 나타낸 것이다.Figure 2 shows the plasma triglyceride concentration of the diabetic animal model in the control group and the herbal composition intake group.
발명의 분야Field of invention
본 발명은 혈장 총 콜레스테롤 및 중성지방의 농도를 감소시키는 효과를 갖는 한약재 추출물을 유효성분으로 함유하는 조성물에 관한 것으로, 보다 구체적으로는 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a composition containing a herb extract having an effect of reducing the concentration of total cholesterol and triglycerides as an active ingredient, more specifically white ginseng, Astragalus, licorice, wolfberry, mulberry leaves, brown roots, vinegar The present invention relates to a pharmaceutical composition for the prevention or treatment of coronary heart disease or atherosclerosis, which comprises a Chinese herbal extract consisting of, ogalpi, schisandra chinensis, golden, powdered, yellow, peony and raw.
배경기술Background
당뇨병은 인슐린 분비가 감소되거나 인슐린의 기능이 저하되어 체내의 세포가 당을 이용하지 못하여 고혈당이 나타나는 질환이다. 당뇨병의 경우 인슐린을 비롯한 호르몬 불균형으로 탄수화물, 단백질, 지질 및 전해질 대사 등 생리적 대사 조절 기능 이상으로 고혈당의 특징적인 증세를 나타내며(Gonuth, S.M., Ann . Intern. Med ., 79, 812-822, 1973), 이러한 고혈당 증세가 지속되면 혈액순환 장애, 망막손상, 신경세포 손상, 신장 기능 저하 및 혈관 합병증 등 심각한 만성적 합병증을 가져오게 된다 (Kannel, W.B., et al., JAMA , 241, 2035-2038, 1979). Diabetes mellitus is a disease in which hyperglycemia occurs because cells in the body cannot use sugar due to reduced insulin secretion or reduced insulin function. In diabetes, hormone imbalance, including insulin, is characteristic of hyperglycemia due to abnormal physiological metabolic control functions such as carbohydrate, protein, lipid and electrolyte metabolism (Gonuth, SM, Ann . Intern. Med . , 79, 812-822, 1973 If these hyperglycemic symptoms persist, serious chronic complications such as blood circulation disorders, retinal damage, nerve cell damage, renal insufficiency and vascular complications may occur (Kannel, WB, et. al ., JAMA , 241, 2035-2038, 1979).
특히, 정상인에 비해서 당뇨환자는 동맥경화증, 뇌경색, 뇌혈전, 심근경색과 같은 심혈관계 질환의 발병률이 높다 (Fuller, J.H., Lancet , 1, 1373-1376, 1980). 당뇨병환자는 관상동맥질환이나 뇌혈관질환에 의한 사망 위험률이 높고, 이는 고혈압, 고지혈증, 비만 등에 의해 흔히 발병된다 (허갑범, 한국영양학회 초록발표논문집, 15-18, 1984). In particular, diabetics have a higher incidence of cardiovascular diseases such as atherosclerosis, cerebral infarction, cerebral thrombosis, and myocardial infarction (Fuller, JH, Lancet , 1, 1373-1376, 1980). Diabetes patients have a high risk of death from coronary artery disease or cerebrovascular disease, which is often caused by hypertension, hyperlipidemia, obesity, etc. (Ho, Bum-beom, The Korean Journal of Nutrition, 15-18, 1984).
제2형 당뇨환자는 중성지방 및 콜레스테롤 농도가 증가하고 HDL-콜레스테롤이 감소하는 지질대사의 이상이 일어나며(Goldberg, R.B., Diabetes Care , 4, 561-572, 1981), 이것은 당뇨 합병증인 관상동맥 질환의 원인이 된다 (Reaven, J.W., Am. J. Med ., 83, 31-40, 1987). 제2형 당뇨환자 중 67%가 한 종류 또는 그 이상의 지질대사 이상을 가진다고 보고되었다 (Harris, M.I., Diabetes Care, 23, 754-758, 2000). Type 2 diabetics have increased lipid metabolism with increased triglyceride and cholesterol levels and decreased HDL-cholesterol (Goldberg, RB, Diabetes). Care , 4, 561-572, 1981), which causes coronary artery disease, a complication of diabetes (Reaven, JW, Am. J. Med ., 83, 31-40, 1987). 67% of people with type 2 diabetes reported one or more types of lipid metabolism (Harris, MI, Diabetes) Care , 23, 754-758, 2000).
당뇨환자에 있어서 관상동맥성 심장질환, 동맥경화증 등의 혈관성 질환의 발 병률은 비당뇨인의 2 내지 6배에 이르는 것으로 알려져 있으며, 심순환계 합병증은 당뇨환자의 주된 사망요인이 되고 있다. 또한 당뇨환자의 눈은 다른 기관들과 마찬가지로 당뇨병에 의한 대사 장해에 의해 손상 받기 쉬운데, 당뇨병에 의해 증가된 비효소적 당화(glycosylation), 단백질과 지질의 산화, 그리고 환원형 글루타치온(glutathione)의 감소는 유해물질에 대한 피부의 저항성을 감소시키고 수정체의 혼탁과 백내장을 유발한다 (Yarat A., et al., Free Rad . Biol . Med ., 31(9), 1038-1042, 2001).In diabetic patients, the incidence of vascular diseases such as coronary heart disease and atherosclerosis is known to be two to six times higher than that of non-diabetic patients, and cardiovascular complications are the leading cause of death for diabetic patients. In addition, diabetic eyes, like other organs, are susceptible to metabolic disorders caused by diabetes, including increased non-enzymatic glycosylation, oxidation of proteins and lipids, and reduced glutathione. Decreases the skin's resistance to harmful substances and leads to clouding of the lens and cataracts (Yarat A., et al ., Free Rad . Biol . Med ., 31 (9), 1038-1042, 2001).
한약재의 지질대사 저하효과에 관한 연구 결과는 다양하나, 특정 한약재의 혼합으로 제조된 한약재 조성물의 질병 예방 관련 연구결과는 미비한 실정이고, 현재까지 한약재 조성물의 효능에 대해 특허출원된 것으로는 사상의학에 의한 체질별 주류 조성물 및 그 제조방법이 전부이다. 이에 본 발명자들은 갈근, 황금 및 고본의 추출물 및 이들을 포함하는 한약재 조성물이 지질대사교란으로 인한 당뇨합병증의 예방 또는 치료에 효과가 있음을 확인하였다.The results of studies on the lowering of lipid metabolism of herbal medicines are diverse, but the results of disease prevention related studies of herbal medicines prepared by mixing specific Chinese herbal medicines are inadequate. Constitutional alcohol composition by the constitution and methods for producing the same are all. Accordingly, the present inventors have confirmed that the extracts of brown root, golden and hard bones and herbal compositions containing them are effective in preventing or treating diabetic complications caused by lipid metabolism disturbance.
상기 한약재 조성물을 구성하는 주요 생약으로는 흰양삼(Panax ginseng C. A . Meyer), 황기(Astragalus membranaceus), 감초(Glycyrrhiza uralensis), 구기자(Lycium chinense), 뽕나무잎(Morus), 갈근(Pueraria thunbergiana), 하고초(Prunella vulgaris var . lilacina), 오갈피(Acanthopanax sessiliflorus), 오미자(Schizandra chinensis), 황금(Scutellaria baicalensis), 산약(Dioscorea batatas), 황정(Polygonatum odoratum var . pluriflorum), 작약(Paeonia lactiflora) 및 생지(Rehmannia glutinosa)가 있다.The main herbal medicine constituting the herbal composition is white ginseng ( Panax ginseng C. A. Meyer ), Astragalus membranaceus ), licorice ( Glycyrrhiza uralensis ), wolfberry ( Lycium) chinense ), Morus leaves, Pueraria thunbergiana ), Prunella vulgaris var . lilacina ), Acanthopanax sessiliflorus ), Schizandra chinensis ), golden ( Scutellaria baicalensis ), mountain drugs ( Dioscorea batatas ), Hwangjeong (Polygonatum odoratum var . pluriflorum ), Peony (Paeonia lactiflora ) and dough ( Rehmannia glutinosa ).
흰양삼(Panax ginseng C. A . Meyer)은 홍삼의 한 등급으로 뿌리는 약용하며 그 형태가 사람 형상이므로 인삼이라 한다. 인삼은 예로부터 불로·장생·익기(益氣)·경신(輕身)의 명약으로 일컬어진다. 한국에서 재배되는 인삼의 뿌리는 비대근으로 원뿌리와 2∼5개의 지근으로 되어 있고 미황백색이다. 지근의 수는 토질, 이식방법, 비료, 수분 등에 의해서 차이가 있으나, 분지성이 강한 식물이며 뿌리의 형태는 나이에 따라 차이가 있고 수확은 4∼6년근일때 한다. 한국 전매품인 홍삼의 원료로 쓰이는 것은 모두 6년근이다. 6년근의 동체는 길이 7∼10 ㎝, 지름 2.5 ㎝ 내외이고 뿌리 길이는 34 ㎝, 무게 80 g 정도이다. 인삼은 매년 땅속줄기에서 싹이 나오고 가을에는 줄기와 잎이 고사하는데 고사한 줄기는 흔적이 남는다. White ginseng ( Panax ginseng C. A. Meyer ) is a grade of red ginseng and its root is medicinal and its form is called human ginseng. Ginseng is said to be the old medicine of Buddha, Jangsaeng, Ikgi, and Shinshin. The root of ginseng cultivated in Korea is hypertrophy, consisting of one root and two to five roots, and pale yellow white. The number of roots is different depending on soil quality, transplantation method, fertilizer, water, etc., but it is a strong branching plant, and the shape of root varies according to age. Six years old is used as a raw material for red ginseng, a Korean monopoly. The six-year-old fuselage has a length of 7-10 cm, a diameter of 2.5 cm, and a root length of 34 cm and a weight of 80 g. The ginseng shoots from the underground stem every year, and the stems and leaves die in autumn, but the dead stems remain.
황기(Astragalus membranaceus)는 콩과로, 이뇨·소종 등의 효능이 있어 신체허약, 피로권태, 기혈허탈, 탈항, 자궁탈, 내장하수, 식은땀, 말초신경 등에 처방한다. 약초로서 재배하며 한방에서는 가을에 채취하여 노두와 잔뿌리를 제거하고 햇빛에 말린 것을 한약재의 황기라 한다. Astragalus membranaceus ( Astragalus membranaceus ) is a legume, diuretic, small-species, such as the effects of physical weakness, fatigue boredom, deprivation of blood, prolapse, uterine deprivation, visceral sewage, cold sweat, peripheral nerves. It is cultivated as an herb, and it is harvested in the fall of Korea to remove outcrops and roots, and dried in sunlight.
감초(Glycyrrhiza uralensis)의 꼬투리는 선처럼 가늘고 긴 모양으로 활처럼 굽으며 신장형의 종자가 6∼8개씩 들어 있다. 뿌리는 단맛이 나서 감미료, 한약재로 사용한다. 시베리아산(G. glabra var . glandulifera), 에스파냐산(G. glabra) 등이 있으며 비슷한 종으로는 개감초(G. pallidiflora)가 있다. 이는 단맛이 적고 감초와 달리 약용으로 쓰이지 않으며, 털이 적고 열매가 타원형이며 끝이 뾰족하고 중국 동북부와 시베리아, 몽골 등지에 분포한다. licorice(Glycyrrhiza uralensis) The pod is thin and long like a line and bent like a bow and contains 6 ~ 8 seeds. The root is sweet, so use it as a sweetener or herbal medicine. SiberianG. glabra var . glandulifera), Mount Espana (G. glabra) And similar species are persimmonG. pallidifloraThere is). It has little sweetness and is not used for medicinal purpose unlike licorice. It has little hair, fruit is oval, pointed and distributed in northeastern China, Siberia and Mongolia.
구기자(Lycium chinense)는 구기자나무의 열매로 단백질, 지방, 당질, 칼 슘, 인, 철분, 베타인, 루틴, 비타민(A, B1, B2, C) 등이 들어 있어 흡수가 빠르다. 한방에서는 강장제·해열제로 쓰고 간기능 보호 작용이 뛰어나 부작용이 별로 없다. 시력을 좋게 하고 당뇨병 등의 성인병을 예방하며 폐와 신장의 기능을 좋게 하고, 들기름과 섞어 숙성해 두었다가 머리에 바르면 흰머리가 생기는 것을 막아 주고 화상에도 효과가 있다고 알려져 있다. 수술 뒤나 회복기에 가루나 즙을 넣어 죽을 끓여 먹기도 하며 술을 담그기도 하는데, 허약체질을 보하는 강장제로 알려져 있다. 술을 조금 섞고 설탕을 넣어 잼을 만들기도 한다.Wolfberry ( Lycium chinense ) is the fruit of Goji berry, which contains protein, fat, sugar, calcium, phosphorus, iron, betaine, rutin, and vitamins (A, B1, B2, C). In oriental medicine, it is used as a tonic and antipyretic. It is known to improve eyesight, prevent adult diseases such as diabetes, improve the function of lungs and kidneys, and mix it with perilla oil, and then apply it to the hair to prevent the formation of gray hair and to burn. After the operation or recovery period, put powder or juice to boil porridge and soak alcohol. It is known as a tonic to weaken the constitution. A little alcohol is mixed with sugar to make jam.
뽕나무잎(Morus)은 쌍떡잎식물 쐐기풀목 뽕나무과 뽕나무속에 속한 낙엽교목 또는 관목의 총칭이며, 원산지는 온대·아열대 지방이며 세계에 30여 종이 있는데 한국에는 산상(山桑: M. bombycis), 백상(白桑: M. alba), 노상(魯桑: M. lhou)의 3종이 재배되고 그 중에서 백상이 가장 많이 재배된다. 잎은 누에를 기르는 데 이용되며, 열매를 오디라고 하는데 술을 담그거나 날것으로 먹는다. 뿌리껍질은 한방에서 해열, 진해, 이뇨제, 소종에 쓰고 목재는 가구재로 이용한다. Morus is a generic name for deciduous trees or shrubs belonging to the dicotyledonous nettle mulberry and mulberry, and its origin is temperate and subtropical, and there are about 30 species in the world. In Korea, M. bombycis and Baeksang (白)桑: M. alba), street (魯桑: 3 and paper cultivation of M. lhou) among Whites is grown most. Leaves are used to raise silkworms, and the fruit is called audi, which is dipped or eaten raw. Root bark is used for fever, Jinhae, diuretic, and small species in oriental medicine and wood is used for furniture.
갈근(Pueraria thunbergiana)은 칡뿌리의 껍질을 벗겨 잘게 썰어서 소금물 또는 백반수에 담갔다가 말린 것인데, 겉은 회백색의 섬유성이고 맛이 좀 쓰다. 성분은 녹말이며 한방에서는 발한 ·해열 ·완하제(緩下劑)로서 고열, 두통, 고혈압, 심부전, 설사, 어깨가 결릴 때 등에 처방한다. 갈근탕은 감기약으로서 유명하다.Brown root ( Pueraria thunbergiana ) is peeled and finely chopped root roots, soaked in brine or white rice and dried. The outer surface is grayish white and tastes bitter. The ingredient is starch and herbal medicine is a sweating, antipyretic, laxative (緩 下 劑) and is prescribed for high fever, headache, high blood pressure, heart failure, diarrhea and shoulder stiffness. Galguntang is famous as a cold medicine.
하고초(Prunella vulgaris var . lilacina)는 길이 1.6mm 정도의 황갈색으로, 열매는 분과(分果: 분열과에서 갈라진 각 열매)이다. 봄에 어린순을 식용한다. 생약 하고초(夏枯草)는 꽃이삭을 말린 것이며, 한방에서는 임질, 결핵, 종기, 전신수 종, 연주창에 약으로 쓰고 소염제·이뇨제로도 쓴다. 한국, 일본, 중국, 타이완, 사할린, 시베리아 남동부 등 한대에서 온대에 걸쳐 분포한다. 비슷한 종류로 흰색 꽃이 피는 것을 흰꿀풀(For . albiflora), 붉은 꽃이 피는 것을 붉은꿀풀(For . lilacina), 줄기가 밑에서부터 곧추서고 기는줄기가 없으며 짧은 새순이 줄기 밑에 달리는 것을 두메꿀풀(For. aleutica)이라고 한다. Prunella vulgaris var . lilacina ) is yellowish brown, about 1.6mm long, and fruit is branched. Eat young shoots in the spring. Herbal Hagocho (夏枯草) is dried flower ear, and in oriental medicine, gonorrhea, tuberculosis, boil, systemic species, playing window, and writes as anti-inflammatory and diuretic. It is distributed in temperate regions of Korea, Japan, China, Taiwan, Sakhalin, and southeastern Siberia. White Lamiaceae that a similar kind of blooming white flowers (For. Albiflora), red flower red Lamiaceae the blood (For. Lilacina), stems standing upright from the bottom there is no group stem dume that short sprouts running under the stem Lamiaceae (For aleutica ).
오갈피(Acanthopanax sessiliflorus)는 꽃이 8∼9월에 피고 자줏빛이며 작은꽃줄기가 짧고 꽃이 산형꽃차례에 밀생한다. 꽃잎은 5개, 암술대는 끝까지 합쳐진다. 열매는 핵과로 다소 편평한 타원형이며 10월에 검게 익는다. 뿌리껍질을 오갈피라고 하며 한방에서 강장제 및 진통제로 사용하고, 수피는 오갈피술을 만드는 데 쓰는 방향성 식물이다. 한국, 중국, 우수리, 아무르 등지에 분포한다. Acanthopanax sessiliflorus ) Flowers bloom in August-September, purplish, small flower stems are short, and flowers grow in inflorescences. The petals are five and the style is combined to the end. Fruits are nucleus, somewhat flat oval, ripening in October. Root bark is called Ogalpi, and it is used as a tonic and painkiller in oriental medicine, and bark is an aromatic plant used to make Ogalpisul. It is distributed in Korea, China, Ussuri, and Amur.
오미자(Schizandra chinensis)는 시잔드린, 고미신, 시트럴, 사과산, 시트르산 등의 성분이 들어 있어 심장을 강하게 하고 혈압을 내리며 면역력을 높여 주어 강장제로 쓴다. 폐 기능을 강하게 하고 진해·거담 작용이 있어서 기침이나 갈증 등을 치료하는 데 도움이 된다. 말린 열매를 찬물에 담가 붉게 우러난 물에 꿀, 설탕을 넣어 음료로 마시거나 화채나 녹말편을 만들어 먹는다. 밤, 대추, 미삼을 함께 넣고 끓여 차를 만들거나 술을 담그기도 한다. Schizandra chinensis ) contains ingredients such as xanthrin, gomisin, citric acid, malic acid, citric acid, etc., which strengthen the heart, lower blood pressure, and increase immunity, which is used as a tonic. Strong lung function and antitussive, expectorant action to help treat coughs and thirst. Soak dried fruit in cold water, add honey and sugar to reddish water, drink it as a drink, or make a flower or starch. Boil chestnuts, jujube, and samsam together to make tea or make alcohol.
황금(Scutellaria baicalensis)은 쌍떡잎식물 통화식물목 꿀풀과의 여러해살이풀로 4개의 수술 중 2개는 길고 암술은 1개이며 씨방은 4개로 깊게 갈라진다. 열매는 9월에 결실하며 둥근 모양으로 꽃받침 안에 들어 있다. 원뿌리는 원뿔형이고 살이 황색이다. 한방에서 뿌리를 해열·이뇨·지사·이담 및 소염제로 이용한다. 약용식물로 재배하며 한국·중국·몽골 및 시베리아 동부 등지에 분포한다.Golden ( Scutellaria baicalensis ) is a perennial herb of dicotyledon and calliflora nectar . Two of four stamens are long, one has pistil, and the ovary is deeply divided into four. Fruits are fruiting in September, rounded in calyx. The cone is conical and the flesh is yellow. In oriental medicine, roots are used as antipyretic, diuretic, branch, yedam and anti-inflammatory drugs. It is cultivated as a medicinal plant and is distributed in Korea, China, Mongolia, and eastern Siberia.
산약(Dioscorea batatas)은 마과(科: Disocoreaceae)에 속한 덩굴성 참마(Disocorea japonica) 또는 마(Disocorea batatas)의 덩이뿌리로 가을 상강 후부터 동지 사이에 채취하여 건조한 것으로, 외면은 백색 또는 황갈색을 띠고 내부는 분질 또는 호화(糊化)된 각질로 단단하다. 성분은 전분, 점액질, 단백질, 지방, 아르기닌콜린 등과 디아스타제를 함유하고 있으며 지라, 폐, 콩팥, 위, 간의 경락(經絡)에도 작용한다. 효능으로 식욕이 감퇴하며 원기가 부족할 때는 백출(白朮), 연밥, 인삼 등과 함께 달여 복용하며, 정액이 새거나 잠잘 때 식은땀을 흘릴 경우 숙지황, 산수유 등과 달여 복용한다. 몸이 마르고 원기가 부족한 경우 인삼, 패모, 복령, 행인 등을 배합해서 달여 복용하면 좋다고 알려져 있다. 당뇨병에도 매일 달여 장기간 차 대신 복용하면 효과가 있다고 알려져 있으나, 염증성 설사를 하거나 대변이 굳을 때는 복용을 중지한다.Yam (Dioscorea batatas) is magwa (科: Disocoreaceae) vine yam belongs to (Disocorea japonica ) or hemp ( Disocorea It is a tuber of batatas , collected between autumn and winter seasons, and dried. The outer surface is white or yellowish brown, and the inside is solid or powdered keratin. Ingredients contain starch, mucus, protein, fat, arginine choline and other diastases, and act on the meridians, lungs, kidneys, stomach and liver. When the appetite is reduced and energy is insufficient, it is taken monthly with Baekchul, white rice, ginseng and so on. If your body is dry and lacking in energy, ginseng, famo, bokyeong, passersby, etc., is known to be a good combination. Even if you take diabetes every month for a long time instead of tea, it is known to be effective, but when you have inflammatory diarrhea or stool harden, stop taking it.
황정(Polygonatum odoratum var . pluriflorum)은 잎 뒷면에 유리조각 같은 돌기가 있고 꽃의 길이가 2∼2.5 ㎝인 것을 산둥굴레(Var . thunbergii), 잎 뒷면 맥 위에 잔 돌기가 많고 꽃이 1∼4개씩 달리는 것을 큰둥굴레(Var . maximowiczii), 잎은 길이 16 ㎝, 나비 5 ㎝ 정도이고 꽃이 4개씩 달리는 것을 맥도둥굴레(P. koreanum), 전체가 크고 잎 뒷면에 털이 있으며 꽃이 2∼5개씩 달리는 것을 왕둥굴레(P. robustum)라고 한다. 봄철에 어린 잎과 뿌리줄기를 식용한다. 생약의 위유는 뿌리줄기를 건조시킨 것이며, 한방에서는 뿌리줄기를 번갈, 당뇨병, 심장쇠약 등의 치료에 사용하며 한국, 일본, 중국에 분포한다.Hwangjeong (Polygonatum odoratum var . pluriflorum) is greater that the projections Polygonatum such a piece of glass and there are many mountains that the length of the flower 2~2.5 ㎝ Polygonatum (Var. thunbergii), turning over the leaves cup the back of the Mac running Flowers 1-4 on the back of each leaf (Var . maximowiczii), leaf length is 16 ㎝, butterfly about 5 ㎝ and are hairy on McDonagh Polygonatum (P. koreanum), the entire back of the leaves large flower that is run by one fourth king that Polygonatum each flower 2-5 run (P. robustum ). Eat young leaves and rhizomes in spring. The crude oil of the herbal medicine is the dried root stem, and in oriental medicine, it is used for the treatment of alternating root stem, diabetes, and heart failure, and is distributed in Korea, Japan, and China.
작약(Paeonia lactiflora)은 꽃이 아름다워 원예용으로 쓴다. 뿌리는 진통, 복통, 월경통, 무월경, 토혈, 빈혈, 타박상 등의 약재로 쓰인다. 중국에서는 진(晉)과 명(明)시대에 이미 관상용으로 재배되어 그 재배 역사는 모란보다 오래되었다. 송(宋)을 거쳐 청(淸)시대에는 수십 종류의 품종이 기록되어 있다. 한국, 몽골, 동시베리아 등지에 분포하는 것으로 알려져 있다. Peeonia lactiflora ) is beautiful for flowers and is used for gardening. Root is used as a medicine such as pain, abdominal pain, dysmenorrhea, amenorrhea, hemostasis, anemia, bruises. In China, it was already cultivated for ornamental purposes during the Qin and Ming times, and its cultivation history is older than that of peonies. Dozens of varieties are recorded in the Qing Dynasty after the Song. It is known to be distributed in Korea, Mongolia and East Siberia.
생지(Rehmannia glutinosa)는 중국이 원산지이고 약용식물로 재배한다. 한방에서는 뿌리의 생것을 생지황, 건조시킨 것을 건지황, 쪄서 말린 것을 숙지황이라고 한다. 숙지황은 보혈제로 쓰이고 생리불순, 허약 체질, 어린이의 발육 부진, 치매, 조루증, 발기부전에 사용하며 생지황은 허약 체질, 토혈, 코피, 자궁 출혈, 생리불순, 변비에 사용하고 건지황은 열병 후에 생기는 갈증과 장기 내부의 열로 인한 소갈증에 효과가 있으며 토혈과 코피를 그치게 하는 것으로 알려져 있다(브리태니커 온라인 백과사전).Dough ( Rehmannia glutinosa ) is native to China and is grown as a medicinal plant. In Chinese medicine, raw raw sulfur of raw roots, dried dried guernsey yellow, steamed dried sujijihwang is called. Sukjihwang is used as a blood donor, menstrual disorders, weak constitution, poor development of children, dementia, premature ejaculation, erectile dysfunction. It is effective for heat thirst and internal organs and is known to stop hemorrhage and nosebleeds (Brittanicer Online Encyclopedia).
그러나, 실제로 상기한 문헌들 및 연구 보고에서 상기 한약재의 지질대사에 대한 치료 효과는 전혀 보고된 바 없다. In fact, however, the therapeutic effects of the herbal medicines on lipid metabolism have not been reported in the above-mentioned documents and research reports.
대한민국 등록특허 10-0052207에서는 갈근, 향부자, 상백피, 맥문동, 천문동, 황련, 치자, 황금, 박하, 죽엽, 활석, 석고, 대황, 황백, 반하, 백삼, 감초, 육계, 괄루인, 진피, 지모, 한수석, 산사, 신곡, 지실, 당귀, 백작약, 숙지황, 백출, 황기, 백복령, 연자육, 산약, 육종용, 오미자, 망초, 지골피, 연교, 후박, 우슬, 자단향, 사상자, 비해, 구기자, 복분자, 맥아, 산수유, 목단피, 육두구, 소백피, 익지인, 목통, 백자인, 석곡, 천궁, 행인, 목과, 청피, 금은화, 황정, 토사자, 석창포 및 용안육을 함유하는 생약 유래 식이성 섬유와 약제학적으로 허용가능한 담체를 포함하는 것을 특징으로 하는 당뇨병 치료제에 대해 기재되어 있고, 대한민국 등록특허 10-0189513에는 맥문동, 지모, 숙지황, 복령, 백삼, 감초, 석고 및 사인을 함유하는 당뇨병 치료제에 대해 기재되어 있으나, 이는 혈당 강하에 효과가 있을 뿐, 콜레스테롤 및 중성지방의 농도를 감소시켜 지질대사 및 당뇨병에 의한 합병증의 예방 및 치료에는 효과를 나타내지 않는다. Republic of Korea Patent Registration 10-0052207 in the roots, hyangbuja, Sangbaekpi, Mcmundong, astronomical dong, rhubarb, gardenia, golden, peppermint, bamboo leaf, talc, gypsum, rhubarb, yellowish white, half, white ginseng, licorice, broiler, walnut, dermis, jimo, Hansuseok, Sansa, Singok, Jisil, Dongguk, Earl, Sukjihwang, Baekchul, Hwanggi, Baekbokryeong, Yeonjak, Sankyun, Breeding, Schisandra chinensis, Forget-me-not, Jigolpi, Yeongwa, Hakja, Wooseol, Rosewood incense, Casualties, Compare, Gugija, Bokbunja, Malt, Dietary fiber and pharmaceutically acceptable carriers containing herbal, corn, bark, nutmeg, cattle baekpi, ripe, wooden, white porcelain, stone, cheonggung, passerby, throat, green skin, sterling silver, yellow, earthenware, stone spear and longan It is described with respect to the diabetes treatment, characterized in that, including the Republic of Korea Patent No. 10-0189513 is described for the diabetes treatment containing Macmundong, jimo, Sukjiwang, Bokryeong, white ginseng, licorice, gypsum and sign However, it is effective only in lowering blood glucose, but not in the prevention and treatment of complications caused by lipid metabolism and diabetes by reducing the concentration of cholesterol and triglycerides.
대한민국 등록특허 10-0543341에는 대극, 강후박, 초갈근 및 감초를 포함하는 당뇨합병증 예방 및 치료용 조성물이 당뇨성 망막병증, 당뇨성 백내장, 당뇨성 신증, 당뇨성 신경병증에 효과가 있는 것으로 기재되어 있으나, 지질대사교란으로 인한 관상동맥성 심장질환, 동맥경화 등의 심혈관 질환 등에는 효과를 나타내지 않는다.Korean Patent Registration No. 10-0543341 discloses that the composition for preventing and treating diabetic complications including diaphragm, ganghwabak, gallbladder and licorice is effective in diabetic retinopathy, diabetic cataract, diabetic nephropathy and diabetic neuropathy. However, it has no effect on cardiovascular diseases such as coronary heart disease and atherosclerosis caused by lipid metabolism disturbance.
또한, 대한민국 등록특허 10-0516180에는 상엽, 황기, 산사육, 초결명, 갈근, 단삼, 하수오, 황정, 대하엽, 구기자, 백봉령, 백출, 의이인 및 인진호를 함유하는 고지혈증 치료제에 대해 기재되어 있고, 대한민국 공개특허 10-2006-0007105에는 하수오, 택사, 오미자, 결명자, 차조기, 산수유, 산사자, 강황, 휘청, 반하, 익지, 도인, 방기 및 곤약을 함유하는 고지혈증 치료제에 대해 기재되어 있으나, 콜레스테롤 및 중성지방의 농도를 감소시켜 고지혈증치료제로 사용될 뿐 당뇨병에 의한 합병증의 예방 또는 치료에 대한 효과는 기재되어 있지 않다.In addition, the Republic of Korea Patent No. 10-0516180 discloses a drug for treating hyperlipidemia containing the upper leaf, Astragalus, mountain breeding, ultra-determinant, brown root, Dansam, Sewao, yellow Jung, large leaf, Gugija, Baekbongryeong, Baekchul, Uiin and Injinho, Korea Patent Publication No. 10-2006-0007105 discloses a drug for treating hyperlipidemia containing sewage, taxa, Schizandra chinensis, deficiency, perilla, cornus, hawthorn, turmeric, whiskers, halves, raw, caucus, antiseptic and konjac, but cholesterol and triglycerides It is used as a drug for treating hyperlipidemia by reducing the concentration of but does not describe the effect on the prevention or treatment of complications caused by diabetes.
이에 본 발명자들은 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료에 효과가 있는 천연 추출물을 개발하고자 예의 노력한 결과, 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물이 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료에 탁월한 효과가 있다는 것을 확인하고 본 발명을 완성하게 되었다.Therefore, the present inventors have made efforts to develop natural extracts effective for the prevention or treatment of coronary heart disease or atherosclerosis, white ginseng, Astragalus, licorice, wolfberry, mulberry leaf, brown root, haechocho, organgalpi, Omija, golden The present invention was completed by confirming that the herbal extracts composed of medicinal herb, yellow flower, peony, and medicinal plant are excellent in preventing or treating coronary heart disease or atherosclerosis.
본 발명의 주된 목적은 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물을 제공하는데 있다.The main object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of coronary heart disease or atherosclerosis containing the herbal extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention contains a Chinese herbal medicine extract consisting of white ginseng, Astragalus, licorice, goji berry, mulberry leaf, brown root, haechocho, ogalpi, Schisandra chinensis, golden, medicinal herb, yellow flower, peony and raw materials as an active ingredient Provided is a pharmaceutical composition for preventing or treating coronary heart disease or atherosclerosis.
본 발명에 있어서, 상기 한약재 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출한 것을 특징으로 할 수 있고, 상기 약학 조성물은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지의 구성비가 1 : 0.7 : 0.4 : 0.7 : 0.4 : 0.7 : 1.1 : 0.9 : 0.4 : 0.4 : 0.7 : 0.7 : 0.9 : 0.9(w/w)인 것을 특징으로 할 수 있으며, 조성물 총 중량에 대하여 한약재 추출물을 0.1 내지 50 중량%로 포함하는 것을 특징으로 할 수 있다.In the present invention, the herbal medicine extract may be characterized in that extracted with water, lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, the pharmaceutical composition is white ginseng, Astragalus, licorice, wolfberry, mulberry leaves, brown root, The composition ratios of Gochucho, Ogalpi, Schisandra chinensis, Golden, Potion, Yellow Crown, Peony and Dough are 1: 0.7: 0.4: 0.7: 0.4: 0.7: 1.1: 0.9: 0.4: 0.4: 0.7: 0.7: 0.9: 0.9 (w / w It may be characterized in that), it may be characterized in that it comprises 0.1 to 50% by weight of the herbal extracts relative to the total weight of the composition.
삭제delete
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 한약재 추출물은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지를 동결건조하여 마쇄한 후, 건조된 시료의 중량의 약 1 내지 20배, 바람직하게는 약 5 내지 15배 분량의 물, 에탄올, 메탄올 등과 같은 C1 내지 C4의 저급알콜 또는 약 1:0.1 내지 1:10, 바람직하게는 1:0.2 내지 1:5의 혼합비(㎏/ℓ)를 갖는 이들의 혼합용매로, 실온에서 약 1 내지 24시간, 바람직하게는 5 내지 15시간 동안 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법을 사용하여, 바람직하게는 냉침 추출한 후 감압 농축함으로써 본 발명의 가용 추출물인 조추출물을 수득할 수 있다.Herbal extract of the present invention is white ginseng, Astragalus, licorice, gojija, mulberry leaves, brown root, gojicho, ogalpi, Schisandra chinensis, golden, medicinal herb, yellow, peony and dough after lyophilization and grinding, the weight of the dried sample About 1 to 20 times, preferably about 5 to 15 times the amount of water, C 1 to C 4 lower alcohols such as ethanol, methanol or the like or about 1: 0.1 to 1:10, preferably 1: 0.2 to 1: As a mixed solvent having a mixing ratio (kg / L) of 5, an extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction for about 1 to 24 hours, preferably 5 to 15 hours at room temperature is used. In this case, the crude extract which is a soluble extract of the present invention can be preferably obtained by cold extraction followed by concentration under reduced pressure.
본 발명의 추출물을 포함하는 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 조성물의 약학적 투여 형태는 이들의 약학적 허용가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. The pharmaceutical dosage forms of the compositions of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. The pharmaceutical compositions according to the invention can be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., respectively, according to conventional methods. Can be. Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출액에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 조성물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다. The composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
삭제delete
삭제delete
삭제delete
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.
실시예Example 1. 한약재 조성물의 제조 및 일반 성분 분석 1. Preparation of Herbal Medicine Composition and Analysis of General Ingredients
시중에서 구입한 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지를 각각 10 g, 7 g, 4 g, 7 g, 4 g, 7 g, 11 g, 9 g, 4 g, 4 g, 7 g, 7 g, 9 g, 9 g씩 섞어 동결건조한 후 마쇄한 후, 하기 실시예의 시료로 사용하였다. Commercially purchased white ginseng, Astragalus, licorice, wolfberry, mulberry leaf, brown root, vinegar, ogalpi, schisandra, golden, medicinal herb, yellow flower, peony and dough 10 g, 7 g, 4 g, 7 g, 4 g respectively , 7 g, 11 g, 9 g, 4 g, 4 g, 7 g, 7 g, 9 g, 9 g each was lyophilized and ground and then used as a sample of the following example.
한약재 조성물의 일반성분은 AOAC법(Association of Official Analytical Chemists, Association of Official Analytical Chemists, 15th ed., 1990)으로 분석하였다. 또한 수분은 상압가열건조법, 조지방은 속실렛(Soxhlet) 추출법, 조단백질은 세미 마이크로(semi-micro) 킬달(Kjeldhal)법, 조회분은 회화법을 이용하여 분석하였으며(식품공전(2005) 일반성분시험법, 한국식품개발연구원), 총식이섬유 함량은 프로스키 등에 의해 개발 수정된 AOAC법으로 측정하였다 (Prosky, L., et al., Journal - Association of Official Analytical Chemists, 71, 1017-1023, 1988). 일반성분의 함량은 100 g당 수분 6.9 g, 지방 1.3 g, 단백질 10.8 g, 회분 14.6 g, 식이섬유 32.8 g으로 나타났다.The general components of the herbal composition were analyzed by AOAC method (Association of Official Analytical Chemists, Association of Official Analytical Chemists, 15th ed., 1990). Moisture was analyzed by atmospheric heating and drying, crude fat by Soxhlet extraction, crude protein by semi-micro Kjeldhal, and crude ash by incineration (Food Code (2005) General Ingredient Test Law, Korea Food Research Institute) and total dietary fiber content was measured by the modified AOAC method developed by Prosky et al. (Prosky, L.,et al.,Journal - Association of Official Analytical Chemists, 71, 1017-1023, 1988). The content of common ingredients was 6.9 g of water, 1.3 g of fat, 10.8 g of protein, 14.6 g of ash, and 32.8 g of dietary fiber per 100 g.
실시예Example 2. 당뇨 동물모델 준비 및 한약재 조성물 실험식이 제조 2. Preparation of Diabetic Animal Model and Preparation of Herbal Medicine Experimental Diet
상기 실시예 1에서 제조한 한약재 추출물의 생체 내(In vivo) 당뇨병 합병증 개선효과를 측정하기 위해, 제2형 당뇨동물 모델인 4주령의 db/db 마우스를(n=12) 평균혈당이 비슷하도록 난괴법으로 분리하여 두 군으로 나누었다. 식이와 식수는 자유롭게 섭취할 수 있도록 하였으며, 사육실의 온도 및 습도는 각각 20~25 ℃, 50~60 %로 유지하였고, 명암은 12시간 간격으로 점등 및 소등을 하였다. 동물 체중과 식이 섭취량은 일주일에 3회 측정하였다. In vivo of the herbal extract prepared in Example 1 ( In vivo ) In order to measure the effects of diabetic complications, four-week-old db / db mice (n = 12), type 2 diabetic animals, were divided into two groups by means of egg masses to have similar mean blood glucose levels. The diet and drinking water were freely ingested. The temperature and humidity of the feeding room were maintained at 20 ~ 25 ℃ and 50 ~ 60%, respectively, and the contrast was turned on and off every 12 hours. Animal weight and dietary intake were measured three times a week.
통계처리시 모든 결과는 평균 ± 표준편차로 나타내었으며, 대조군과 상기 한약재 추출물 섭취군 사이의 유의성 검정은 스튜던트 T -검정(Student's t-test) 을 사용하여 실시하였다 (α = 0.05).All results were statistically represented as mean ± standard deviation, statistical significance between the control group and the herbal extract intake group was performed using the Student's t-test (α = 0.05).
대조군에게는 표 1에 나타낸 기초식이를, 섭취군에게는 기초식이에 실시예 1의 동결건조된 한약재 조성물을 10% 함유한 한약재 조성물 식이를 6주 동안 섭취시켰다. The control group was fed the basic diet shown in Table 1, and the ingestion group was fed the herbal composition composition containing 10% of the lyophilized herbal composition of Example 1 in the basic diet for 6 weeks.
실시예Example 3. 식이 섭취량 및 체중 증가량 측정 3. Measuring Dietary Intake and Weight Gain
체중 및 식이 섭취량 측정결과, 하기 표 2에서 보는 바와 같이 대조군과 한약재 조성물 추출물 식이를 6주간 공급한 섭취군의 체중은 각각 40.4 ± 2.6 g, 39.5 ± 1.6 g 이었으며, 식이 섭취량은 대조군 및 섭취군이 각각 4.47 ± 0.62 g/일, 4.30 ± 0.60 g/일로 유의적인 차이를 나타내지 않았다.As a result of measuring the weight and dietary intake, as shown in Table 2, the weight of the intake group fed the control group and the medicinal herb composition extract diet for 6 weeks was 40.4 ± 2.6 g and 39.5 ± 1.6 g, respectively. 4.47 ± 0.62 g / day and 4.30 ± 0.60 g / day, respectively, showed no significant difference.
실시예Example 4. 혈장 총 콜레스테롤 및 중성지방의 농도 측정 4. Determination of plasma total cholesterol and triglyceride levels
식이 섭취 6주째 실험동물을 희생하였다. 실험동물은 희생하기 전 14시간 동안 절식시킨 후, 이산화탄소 가스로 질식시켜 EDTA(ehylene diamine tetra acetic acid) 10 ㎎을 넣은 주사기로 심장에서 채혈하였다. 혈액은 3,000 rpm에서 15분간 원심분리하여 혈장을 수집한 후 -70 ℃에서 보관하였고, 간 조직은 적출하여 -70℃에서 보관하였다.Animals were sacrificed at 6 weeks of diet. The animals were fasted for 14 hours before sacrifice, suffocated with carbon dioxide gas, and blood was collected from the heart with a syringe containing 10 mg of EDTA (ehylene diamine tetra acetic acid). Blood was collected by centrifugation at 3,000 rpm for 15 minutes to collect plasma and stored at -70 ° C, and liver tissue was extracted and stored at -70 ° C.
혈장 총 콜레스테롤은 살레의 방법(Sale, F.O., et al., Anal . Biochem., 142, 347-348, 1984)에 의해 측정하였다. Plasma total cholesterol is the method of sale (Sale, FO, et. al ., Anal . Biochem. , 142, 347-348, 1984).
살레의 방법이란, 혈청 중에는 유리형 및 에스테르형 콜레스테롤이 존재하며, 에스테르형 콜레스테롤에 콜레스테롤에스테르 가수분해효소(hydrolase)를 반응시키면 유리형과 지방산으로 분해되고, 유리형에 콜레스테롤 산화효소를 반응시키면 H2O2와 δ-콜레스테논(Cholestenone)이 생성되는데, 생성된 H2O2에 과산화효소와 4-아미노안티피린 및 페놀을 동시에 반응시키면 산화적 축합반응으로 퀴논이 생성되며 이를 비색하여 콜레스테롤을 정량하는 방법이다. 상기에서 채취한 혈장을 37 ℃에서 5분간 반응시킨 후 500 ㎚에서 검체 및 표준으로 흡광도를 측정하여 정량하였다. Saleh's method refers to the presence of free and ester cholesterol in serum. When cholesterol ester hydrolase reacts with ester cholesterol, it breaks down into free and fatty acids. 2 O 2 and δ-cholesterone are produced. When the peroxidase, 4-aminoantipyrine and phenol are reacted simultaneously with the produced H 2 O 2 , quinone is produced by oxidative condensation reaction. How to quantify. The plasma collected above was reacted for 5 minutes at 37 ° C., and then absorbance was measured and measured at 500 nm using a sample and a standard.
그 결과, 총 콜레스테롤 농도는 대조군이 185.4±13.7 ㎎/dL, 섭취군이 159.2±18.4 ㎎/dL로 나타났다 (도 1). 이로부터 한약재 조성물 활성성분의 장기간 섭취는 당뇨동물에 있어서 혈장 콜레스테롤 농도를 유의적으로 감소시킴을 확인할 수 있었다 (p<0.05).As a result, the total cholesterol concentration was 185.4 ± 13.7 mg / dL in the control group, 159.2 ± 18.4 mg / dL in the intake group (Fig. 1). From this, it was confirmed that long-term intake of the active ingredient of the herbal composition significantly decreased plasma cholesterol concentration in diabetic animals (p <0.05).
혈장 중성지방은 부오콜의 방법(Buoccole, G., David, H., Clin . Chem ., 19, 476, 1973)에 의하여 측정하였다. Plasma triglycerides were measured by Buoccole's method (Buoccole, G., David, H., Clin . Chem ., 19, 476, 1973).
부오콜의 방법이란, 트리글리세라이드는 리파아제에 의해서 글리세롤과 지방산으로 분해되고, 글리세롤은 다시 글리세롤-1-포스페이트로 변화되고, 글리세롤-1-포스페이트는 GPO에 의해 분해되어 H2O2가 생성되는데, 생성된 H2O2는 아미노아티피린 및 TOOS(N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline)와 반응하여 산화적 축합반응으로 적색의 퀴논을 생성하며, 이를 비색하여 중성지방을 정량하는 방법이다. 상기에서 채취한 혈장을 37 ℃에서 5분간 반응시킨 후 546 ㎚에서 검체 및 표준으로 흡광도를 측정하여 정량하였다. In the method of bucolol, triglyceride is decomposed into glycerol and fatty acid by lipase, glycerol is converted into glycerol-1-phosphate, and glycerol-1-phosphate is decomposed by GPO to produce H 2 O 2 . The produced H 2 O 2 reacts with aminoatiphyrin and TOOS (N-ethyl-N- (2-hydroxy-3-sulfopropyl) -3-methylaniline) to produce red quinone by oxidative condensation reaction It is a method of quantifying triglycerides. The plasma collected above was reacted at 37 ° C. for 5 minutes, and then absorbance was measured and measured at 546 nm using a sample and a standard.
그 결과, 혈장 중성지방 농도는 대조군이 108.8±11.0 ㎎/dL, 섭취군이 99.4±15.0 ㎎/dL로 나타났다 (도 2). 이로부터 한약재 조성물 활성성분의 장기간 섭취는 당뇨동물의 중성지방의 농도에 있어서 유의적인 차이는 없으나, 감소하는 경향이 있음을 확인할 수 있었다.
실시예 5. 급성 독성실험 As a result, the plasma triglyceride concentration was 108.8 ± 11.0 mg / dL in the control group and 99.4 ± 15.0 mg / dL in the ingestion group (FIG. 2). From this, the long-term intake of the active ingredient of the herbal composition did not have a significant difference in the concentration of triglycerides in diabetic animals, but it was confirmed that the tendency to decrease.
Example 5. Acute Toxicity Test
삭제delete
6 주령의 특정병원체부재(specific pathogen-free, SPF) SD계 랫트(rat)를 사용하여 급성 독성실험을 실시하였다. 각 그룹당 2마리씩의 동물에 상기의 한약재 추출물을 100 ㎎/㎏ 용량으로 1회 경구투여 하였다. 한약재 추출물 투여 후 동물의 폐사여부, 임상증상 및 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적 검사를 실시하였으며, 부검하여 육안으로 강장기와 흉강 장기의 이상여부를 관찰하였다.Acute toxicity experiments were performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals of each group were orally administered with the above-mentioned herbal extract at a dose of 100 mg / kg. After administration of the medicinal herb extract, the mortality, clinical symptoms, and weight changes of the animals were observed. Hematological and hematological and biochemical tests were performed.
그 결과, 실험 물질을 투여한 모든 동물에서 특기할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사 및 부검 소견 등에서도 독성변화는 관찰되지 않았다. 또한 본 발명의 한약재 추출물은 랫트에서 각각 100 ㎎/㎏까지도 독성변화를 나타내지 않았으며, 경구투여 최소치사량(LD50)이 100 ㎎/㎏이상인 안전한 물질로 판단되었다. As a result, no significant clinical symptoms or dead animals were noted in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. In addition, the herbal extract of the present invention did not show a toxic change even in rats up to 100 mg / kg, respectively, and was determined to be a safe substance having a minimum lethal dose (LD50) of 100 mg / kg or more.
이하, 본 발명의 한약재 추출물을 함유하는 약학 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, the preparation of the pharmaceutical composition containing the herbal extract of the present invention will be described, but the present invention is not intended to limit it, but is intended to explain in detail only.
제제예Formulation example 1. One. 산제의Powder 제조 Produce
한약재 추출물 20 ㎎Herbal Medicine Extract 20 mg
유당 100 ㎎
탈크(Talc) 10 ㎎
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예Formulation example 2. 정제의 제조 2. Preparation of Tablets
한약재 추출물 10 ㎎Herbal Medicine Extract 10mg
옥수수전분 100 ㎎
유당 100 ㎎
스테아린산 마그네슘(Magnesium stearate) 2 ㎎2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components and tableting according to the conventional tablet manufacturing method to prepare a tablet.
제제예Formulation example 3. 캅셀제의 제조 3. Manufacture of capsule
한약재 추출물 10 ㎎Herbal Medicine Extract 10mg
결정성 셀룰로오스 3 ㎎3 mg of crystalline cellulose
락토오스(lactose) 14.8 ㎎Lactose 14.8 mg
스테아린산 마그네슘 0.2 ㎎Magnesium Stearate 0.2mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of Injectables
한약재 추출물 10 ㎎Herbal Medicine Extract 10mg
만니톨(mannitol) 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2974 ㎎Sterile distilled water for injection 2974 mg
Na2HPO4·12H2O 26 ㎎ Na 2 HPO 4 · 12H 2 O 26 ㎎
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
한약재 추출물 20 ㎎Herbal Medicine Extract 20 mg
이성화당(isomerized sugar) 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음, 상기의 성분을 혼합한 후 정제수를 가하여 전체의 용량이 100 ㎖가 되도록 조절해서 갈색병에 충진하여 멸균시킴으로써 액제를 제조한다.By dissolving each component in purified water according to a conventional liquid preparation method, and adding a proper amount of lemon aroma, and then mixing the above components and adding purified water to adjust the total volume to 100 ㎖ by filling in a brown bottle and sterilizing Prepare a liquid formulation.
제제예Formulation example 6. 건강 식품의 제조 6. Manufacture of healthy food
한약재 추출물 1000 ㎎Chinese Herb Extract 1000mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎
비오틴(biotin) 10 ㎍10 μg biotin
니코틴산아미드(nicotinic acid amide) 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산(folic acid) 50 ㎍50 μg folic acid
판토텐산 칼슘(pantothenic acid calcium) 0.5 ㎎Pantothenic acid calcium 0.5 mg
무기질 혼합물 적량Mineral mixture
황산제1철(ferrous sulfate) 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연(zinc oxide) 0.82 ㎎Zinc oxide 0.82 mg
탄산마그네슘(magnesium carbonate) 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨(potassium phosphate monobasic) 15 ㎎Potassium phosphate monobasic 15 mg
제2인산칼슘(potassium phosphate dibasic) 55 ㎎Dibasic calcium phosphate (potassium phosphate dibasic) 55 mg
구연산칼륨(potassium citrate) 90 ㎎Potassium citrate 90 mg
탄산칼슘(calcium carbonate) 100 ㎎
염화마그네슘(magnesium chloride) 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고 통상의 방법에 따라 건강식품 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixtures is a composition suitable for health foods in a preferred embodiment, but the composition ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, and then granulated. It can be prepared and used in the manufacture of health foods according to conventional methods.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
한약재 추출물 100 ㎎Medicinal Herb Extract 100mg
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3g0.3 g of vitamin B2
물 적량Water quantity
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85 ℃에서 교반 가열한 후 여과한다. 이를 멸균된 2 ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components according to the conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour and filtered. It is obtained in a sterile 2 L container, sealed, sterilized and stored in a refrigerated state before use in the manufacture of a healthy beverage composition of the present invention.
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a component suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
이상 상세히 기술한 바와 같이, 본 발명에서는 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물이 혈장의 총 콜레스테롤 농도 및 중성지방의 농도를 감소시킨다는 것을 밝혀내고, 상기 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물을 제공하는 효과가 있다.As described in detail above, in the present invention, the total cholesterol concentration of plasma is composed of white ginseng, Astragalus, licorice, goji berry, mulberry leaf, brown root, hyacinth, ogalpi, Schisandra chinensis, golden, medicinal herb, yellow cherries, peony and dough. And it has been found that reducing the concentration of triglycerides, there is an effect of providing a pharmaceutical composition for the prevention or treatment of coronary heart disease or atherosclerosis containing the herbal extract as an active ingredient.
본 발명에 따르면, 상기 한약재 추출물은 혈장의 총 콜레스테롤 농도 및 중성지방의 농도를 감소시킴으로써, 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 의약품에 이용할 수 있다.According to the present invention, the herbal extracts can be used in medicines for the prevention or treatment of coronary heart disease or atherosclerosis by reducing the total cholesterol concentration and triglyceride concentration in plasma.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다. The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060044651A KR100793204B1 (en) | 2006-05-18 | 2006-05-18 | Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060044651A KR100793204B1 (en) | 2006-05-18 | 2006-05-18 | Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070111623A KR20070111623A (en) | 2007-11-22 |
KR100793204B1 true KR100793204B1 (en) | 2008-01-10 |
Family
ID=39090397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060044651A KR100793204B1 (en) | 2006-05-18 | 2006-05-18 | Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100793204B1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837051A (en) * | 2010-06-11 | 2010-09-22 | 云南红河制药有限公司 | New rhodobryum roseum tablet medicament composition |
WO2010140734A1 (en) | 2009-06-01 | 2010-12-09 | 조선대학교산학협력단 | Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients |
CN102408973A (en) * | 2011-07-11 | 2012-04-11 | 张旺凡 | Rhizoma polygonati health wine and preparation method thereof |
CN103181562A (en) * | 2011-12-31 | 2013-07-03 | 谢鸣 | Health food having effects of life cultivation and health preservation in summer and preparation method thereof |
CN104013894A (en) * | 2014-06-28 | 2014-09-03 | 李文职 | Traditional Chinese medicine (TCM) preparation for treating coronary heart diseases |
CN104147099A (en) * | 2014-08-16 | 2014-11-19 | 黑龙江江恒医药科技有限公司 | Coronary artery-dredging tablet and preparation method thereof |
CN104225420A (en) * | 2014-09-10 | 2014-12-24 | 吴秀花 | Traditional Chinese medicine preparation for treating yin-cold stagnation type coronary heart disease and nursing method |
CN104258041A (en) * | 2014-09-23 | 2015-01-07 | 李常华 | Traditional Chinese medicine composition for treating chest obstruction |
CN105012748A (en) * | 2015-08-07 | 2015-11-04 | 李强 | Traditional Chinese medicine composition for treating chest stuffiness and pains |
CN105194420A (en) * | 2015-11-08 | 2015-12-30 | 长沙佰顺生物科技有限公司 | Medicine composition for preventing and treating coronary heart disease |
CN105267884A (en) * | 2015-11-26 | 2016-01-27 | 王平平 | Medicine for mitral valve combined aortic lesion heart disease |
KR20170041997A (en) | 2015-10-08 | 2017-04-18 | 충남대학교산학협력단 | Composition comprising extract of Acanthopanax koreanum for preventing or treating of vascular disease |
KR20180010961A (en) | 2016-07-21 | 2018-01-31 | 경희대학교 산학협력단 | Composition for preventing, treating or improving muscle atrophy comprising complex extracts |
CN108273007A (en) * | 2018-04-04 | 2018-07-13 | 江苏省中医院 | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment coronary disease and angina pectoris effect |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101027707B1 (en) * | 2008-03-03 | 2011-04-12 | 금산고려홍삼 주식회사 | Gujeung-gupo red ginseng concentrate and method for preparing functional foods for enhanced glucose metabolism |
KR101508395B1 (en) * | 2009-12-28 | 2015-04-08 | 경희대학교 산학협력단 | Composition comprising the extract of Prunella vulgaris L for preventing and treating schizophrenia and amnesia |
KR101045027B1 (en) * | 2010-11-01 | 2011-06-30 | 충남대학교산학협력단 | A composition comprising murrayafoline a for treating and preventing heart disease |
KR101296853B1 (en) * | 2010-11-30 | 2013-08-14 | 원광대학교산학협력단 | A composition for treating or preventing diabetic atherosclerosis comprising the extract of Prunella vulgaris |
KR101502650B1 (en) * | 2011-04-26 | 2015-03-16 | 경희대학교 산학협력단 | Composition for preventing or treating auditory neuropathy comprising red ginseng extracts |
US8586106B2 (en) | 2011-12-06 | 2013-11-19 | The Concentrate Manufacturing Company Of Ireland | Fatigue-relieving herbal extracts and beverages comprising the same |
KR101355508B1 (en) * | 2012-02-10 | 2014-01-29 | 주식회사 에이.비.아이 | Pharmaceutical composition for preventing or treating renal disease comprising schizandrin, gomicin or extract of Schisandra chinensis containing the same as effective component |
US20170239310A1 (en) * | 2014-07-21 | 2017-08-24 | Dongguk University Gyeongju Campus Industry- Academy Cooperation Foundation | Composition for Promoting Anti-Diabetic and Anti-Obesity Effects, Comprising Herbal Extract |
KR101713419B1 (en) * | 2015-07-01 | 2017-03-07 | 김무연 | Pharmaceutical composition for preventing or treating ocular diseases |
KR101988579B1 (en) * | 2016-10-04 | 2019-06-14 | 한국한의학연구원 | A composition containing complex extracts comprising Schisandra chinesis for preventing or treating blood circulation-related diseases |
KR101969236B1 (en) * | 2017-11-29 | 2019-07-22 | 극동대학교 산학협력단 | Oriental Medicine Jelly and Producing Method Thereof |
KR102120483B1 (en) * | 2018-05-24 | 2020-06-08 | 종근당건강 주식회사 | Pharmaceutical composition for preventing or treating of macular degeneration comprising Prunella vulgaris var. lilacina extract as an active ingredient |
WO2021100940A1 (en) * | 2019-11-22 | 2021-05-27 | 종근당건강 주식회사 | Pharmaceutical composition for preventing or treating macular degeneration, containing prunella vulgaris extract as active ingredient |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950002776A (en) * | 1993-07-23 | 1995-02-16 | 이상화 | Hypoglycemic composition |
KR960003608A (en) * | 1994-07-21 | 1996-02-23 | 한동근 | Healthy food composition that improves diabetes |
KR20010105095A (en) * | 2000-05-19 | 2001-11-28 | 박찬우 | Antidiabetic composition and food containing the same |
KR20040003888A (en) * | 2002-07-04 | 2004-01-13 | 주식회사 싸이클로젠 | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus |
KR20040005070A (en) * | 2002-07-08 | 2004-01-16 | 김영일 | Composite of health ancillary food |
KR20050001283A (en) * | 2003-06-28 | 2005-01-06 | 강석중 | Healthy food composition having efficacy of anti-diabetic and its process |
-
2006
- 2006-05-18 KR KR1020060044651A patent/KR100793204B1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950002776A (en) * | 1993-07-23 | 1995-02-16 | 이상화 | Hypoglycemic composition |
KR960003608A (en) * | 1994-07-21 | 1996-02-23 | 한동근 | Healthy food composition that improves diabetes |
KR20010105095A (en) * | 2000-05-19 | 2001-11-28 | 박찬우 | Antidiabetic composition and food containing the same |
KR20040003888A (en) * | 2002-07-04 | 2004-01-13 | 주식회사 싸이클로젠 | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus |
KR20040005070A (en) * | 2002-07-08 | 2004-01-16 | 김영일 | Composite of health ancillary food |
KR20050001283A (en) * | 2003-06-28 | 2005-01-06 | 강석중 | Healthy food composition having efficacy of anti-diabetic and its process |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010140734A1 (en) | 2009-06-01 | 2010-12-09 | 조선대학교산학협력단 | Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients |
CN101837051A (en) * | 2010-06-11 | 2010-09-22 | 云南红河制药有限公司 | New rhodobryum roseum tablet medicament composition |
CN101837051B (en) * | 2010-06-11 | 2011-08-17 | 云南红河制药有限公司 | New rhodobryum roseum tablet medicament composition |
CN102408973A (en) * | 2011-07-11 | 2012-04-11 | 张旺凡 | Rhizoma polygonati health wine and preparation method thereof |
CN103181562A (en) * | 2011-12-31 | 2013-07-03 | 谢鸣 | Health food having effects of life cultivation and health preservation in summer and preparation method thereof |
CN104013894A (en) * | 2014-06-28 | 2014-09-03 | 李文职 | Traditional Chinese medicine (TCM) preparation for treating coronary heart diseases |
CN104147099A (en) * | 2014-08-16 | 2014-11-19 | 黑龙江江恒医药科技有限公司 | Coronary artery-dredging tablet and preparation method thereof |
CN104225420A (en) * | 2014-09-10 | 2014-12-24 | 吴秀花 | Traditional Chinese medicine preparation for treating yin-cold stagnation type coronary heart disease and nursing method |
CN104258041A (en) * | 2014-09-23 | 2015-01-07 | 李常华 | Traditional Chinese medicine composition for treating chest obstruction |
CN105012748A (en) * | 2015-08-07 | 2015-11-04 | 李强 | Traditional Chinese medicine composition for treating chest stuffiness and pains |
KR20170041997A (en) | 2015-10-08 | 2017-04-18 | 충남대학교산학협력단 | Composition comprising extract of Acanthopanax koreanum for preventing or treating of vascular disease |
CN105194420A (en) * | 2015-11-08 | 2015-12-30 | 长沙佰顺生物科技有限公司 | Medicine composition for preventing and treating coronary heart disease |
CN105267884A (en) * | 2015-11-26 | 2016-01-27 | 王平平 | Medicine for mitral valve combined aortic lesion heart disease |
KR20180010961A (en) | 2016-07-21 | 2018-01-31 | 경희대학교 산학협력단 | Composition for preventing, treating or improving muscle atrophy comprising complex extracts |
CN108273007A (en) * | 2018-04-04 | 2018-07-13 | 江苏省中医院 | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment coronary disease and angina pectoris effect |
Also Published As
Publication number | Publication date |
---|---|
KR20070111623A (en) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100793204B1 (en) | Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient | |
KR100795976B1 (en) | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient | |
KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR100795822B1 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tee including the same as effective components and the preparation method thereof | |
KR101347826B1 (en) | A composition comprising the combined extract of ISRK for preventing and treating diabetes mellitus and diabetic complication | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
KR100793205B1 (en) | Health Supporting Foods for Improving Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient | |
CN105962310A (en) | Inflammation-free chilli sauce | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR101195109B1 (en) | composition of health food | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
KR100923043B1 (en) | Blood pressure therapeutic agent for chinese medicine and manufacture method thereof | |
KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
US20080311229A1 (en) | Functional Food Composition For Treating Allergy, Natural Tea Using the Same and the Manufacturing Method Thereof | |
KR101795261B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Treatmenting and Protecting the Insomniac and the Method of Making the Same | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR100865900B1 (en) | Composition comprising an extract of herbal combination(occ-i) or the powder(occ-ii) thereof for preventing and treating diabetes mellitus | |
KR100846521B1 (en) | Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus | |
KR100545407B1 (en) | Food composition for the treatment of the hyperlipidemia and its process | |
KR100761552B1 (en) | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same | |
KR20150061845A (en) | Manufacturing method of composition of enzyme for Disintegration of Human waste in Portable Toilet Bowl and Composition of enzyme for Disintegration of Human waste in Portable Toilet Bowl manufactured by the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121213 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131205 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |